Sanofi Reports Q3 2026 Financial Results and Raises Full-Year Outlook

Sanofi reported a 14.3% increase in third-quarter 2026 sales at constant exchange rates and business earnings per share of €3.55, supported by strong commercial momentum and Dupixent. The company raised its full-year outlook for the second time, now expecting sales growth in the low teens and business EPS growth in the mid teens, excluding currency effects. Its CEO said Sanofi is seeking potential acquisitions to strengthen its medicine pipeline ahead of upcoming patent expirations.